Literature DB >> 22361326

Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.

Youngho Lee1, Danica J Schulte, Kenichi Shimada, Shuang Chen, Timothy R Crother, Norika Chiba, Michael C Fishbein, Thomas J A Lehman, Moshe Arditi.   

Abstract

BACKGROUND: Kawasaki disease (KD) is the most common cause of acute vasculitis and acquired cardiac disease in US children. Untreated, children may develop coronary artery aneurysms, myocardial infarction, and sudden death as a result of the illness. Up to a third of KD patients fail to respond to intravenous immunoglobulin, the standard therapy, and alternative treatments are being investigated. Genetic studies have indicated a possible role for interleukin (IL)-1β in KD. We therefore explored the role of IL-1β in a murine model of KD. METHODS AND
RESULTS: Using an established mouse model of KD that involves injection of Lactobacillus casei cell wall extract (LCWE), we investigated the role of IL-1β and caspase-1 (activated by the inflammasome and required for IL-1β maturation) in coronary arteritis and evaluated the efficacy of IL-1 receptor antagonist as a potential treatment. LCWE-induced IL-1β maturation and secretion were dependent on the NLRP3 inflammasome in macrophages. Both caspase-1-deficient and IL-1 receptor-deficient mice were protected from LCWE-induced coronary lesions. Injection of recombinant IL-1β into caspase-1-deficient mice restored the ability of LCWE to cause coronary lesions in response to LCWE. Furthermore, daily injections of the IL-1 receptor antagonist prevented LCWE-mediated coronary lesions up to 3 days after LCWE injection.
CONCLUSIONS: Our results strongly suggest that caspase-1 and IL-1β play critical roles in the development of coronary lesions in this KD mouse model, blocked by IL-1 receptor antagonist. Therefore, anti-IL-1β treatment strategies may constitute an effective, more targeted treatment of KD to prevent coronary lesions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22361326      PMCID: PMC3337219          DOI: 10.1161/CIRCULATIONAHA.111.072769

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  47 in total

1.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

Authors:  N A Thornberry; H G Bull; J R Calaycay; K T Chapman; A D Howard; M J Kostura; D K Miller; S M Molineaux; J R Weidner; J Aunins
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

2.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

3.  Circulating interleukin-1 beta in patients with Kawasaki disease.

Authors:  C P Maury; E Salo; P Pelkonen
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

4.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

Authors:  J W Newburger; M Takahashi; A S Beiser; J C Burns; J Bastian; K J Chung; S D Colan; C E Duffy; D R Fulton; M P Glode
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

5.  Can we prevent long term cardiac damage in Kawasaki disease? Lessons from Lactobacillus casei cell wall-induced arteritis in mice.

Authors:  T J Lehman
Journal:  Clin Exp Rheumatol       Date:  1993 May-Jun       Impact factor: 4.473

6.  Plasma prostaglandin E2 level in Kawasaki disease.

Authors:  T Lee; S Furukawa; Y Fukuda; K Yabuta; H Kato
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1988-02       Impact factor: 4.006

7.  Gamma globulin re-treatment in Kawasaki disease.

Authors:  R P Sundel; J C Burns; A Baker; A S Beiser; J W Newburger
Journal:  J Pediatr       Date:  1993-10       Impact factor: 4.406

8.  Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension.

Authors:  T J Lehman; S M Walker; V Mahnovski; D McCurdy
Journal:  Arthritis Rheum       Date:  1985-06

Review 9.  Animal models of vasculitis. Lessons we can learn to improve our understanding of Kawasaki disease.

Authors:  T J Lehman; V Mahnovski
Journal:  Rheum Dis Clin North Am       Date:  1988-08       Impact factor: 2.670

10.  Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease.

Authors:  D Y Leung; R S Cotran; E Kurt-Jones; J C Burns; J W Newburger; J S Pober
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

View more
  76 in total

1.  Reduced Platelet miR-223 Induction in Kawasaki Disease Leads to Severe Coronary Artery Pathology Through a miR-223/PDGFRβ Vascular Smooth Muscle Cell Axis.

Authors:  Yuan Zhang; Yanfei Wang; Li Zhang; Luoxing Xia; Minhui Zheng; Zhi Zeng; Yingying Liu; Timur Yarovinsky; Allison C Ostriker; Xuejiao Fan; Kai Weng; Meiling Su; Ping Huang; Kathleen A Martin; John Hwa; Wai Ho Tang
Journal:  Circ Res       Date:  2020-06-29       Impact factor: 17.367

2.  Marked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease.

Authors:  Shuang Chen; Youngho Lee; Timothy R Crother; Michael Fishbein; Wenxuan Zhang; Atilla Yilmaz; Kenichi Shimada; Danica J Schulte; Thomas J A Lehman; Prediman K Shah; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-24       Impact factor: 8.311

Review 3.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

4.  Endothelial Nlrp3 inflammasome activation associated with lysosomal destabilization during coronary arteritis.

Authors:  Yang Chen; Xiang Li; Krishna M Boini; Ashley L Pitzer; Erich Gulbins; Yang Zhang; Pin-Lan Li
Journal:  Biochim Biophys Acta       Date:  2014-11-15

5.  miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.

Authors:  Ming He; Zhen Chen; Marcy Martin; Jin Zhang; Panjamaporn Sangwung; Brian Woo; Adriana H Tremoulet; Chisato Shimizu; Mukesh K Jain; Jane C Burns; John Y-J Shyy
Journal:  Circ Res       Date:  2016-12-06       Impact factor: 17.367

Review 6.  The role of the inflammasome in cardiovascular diseases.

Authors:  Xuan Li; Nicolas Deroide; Ziad Mallat
Journal:  J Mol Med (Berl)       Date:  2014-03-19       Impact factor: 4.599

7.  IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β.

Authors:  Youngho Lee; Daiko Wakita; Jargalsaikhan Dagvadorj; Kenichi Shimada; Shuang Chen; Ganghua Huang; Thomas J A Lehman; Michael C Fishbein; Hal M Hoffman; Timothy R Crother; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

8.  Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-κB signaling pathway in BV-2 microglia.

Authors:  Li Yuan; Yuchen Wu; Xiaomeng Ren; Qian Liu; Jing Wang; Xuebo Liu
Journal:  Mol Cell Biochem       Date:  2013-10-11       Impact factor: 3.396

9.  CD8+ T Cells Contribute to the Development of Coronary Arteritis in the Lactobacillus casei Cell Wall Extract-Induced Murine Model of Kawasaki Disease.

Authors:  Magali Noval Rivas; Youngho Lee; Daiko Wakita; Norika Chiba; Jargalsaikhan Dagvadorj; Kenichi Shimada; Shuang Chen; Michael C Fishbein; Thomas J A Lehman; Timothy R Crother; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

10.  GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency.

Authors:  Ping Ye; Wenhao Chen; Jie Wu; Xiaofan Huang; Jun Li; Sihua Wang; Zheng Liu; Guohua Wang; Xiao Yang; Peng Zhang; Qiulun Lv; Jiahong Xia
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.